Status:
COMPLETED
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Lead Sponsor:
Fudan University
Conditions:
The Patients With CRLM Who Benefit More From Bevacizumab
Eligibility:
All Genders
18-75 years
Brief Summary
This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive unresectable colorectal cancer liver metastases, prov...
Detailed Description
Accurately predicting tumor response to targeted therapies is essential for guiding personalized conversion therapy in patients with unresectable colorectal cancer liver metastases (CRLM). Currently, ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years and ≤75 years;
- Patients were histologically confirmed for colorectal adenocarcinoma with unresectable liver-limited or liver-dominant metastases
- PET/CT at baseline were available
- First line treated with FOLFOX+ bevacizumab.
Exclusion
- Resectable liver metastases;
- Wide-type KRAS/NRAS;
- No measurable liver metastasis;
- No efficacy assessment;
- No follow-up information.
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
307 Patients enrolled
Trial Details
Trial ID
NCT06023173
Start Date
October 1 2013
End Date
January 1 2023
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Zhongshan Hospital, Fudan University
Shanghai, China